Palisade Bio Strengthens IBD Advisory Board Ahead of Phase 2 Trials
Event summary
- Palisade Bio added two IBD experts, Laurent Peyrin-Biroulet and David T. Rubin, to its Clinical Advisory Board.
- PALI-2108 Phase 2 IND submission for ulcerative colitis planned for H1 2026.
- PALI-2108 showed 100% clinical response in Phase 1b UC cohort with no serious adverse events.
- PALI-2108 targets intestinal fibrosis and fibrostenotic Crohn’s disease, an area with limited therapeutic options.
The big picture
Palisade Bio is positioning itself as a leader in next-generation IBD therapeutics by leveraging targeted PDE4 inhibition. The appointments of Peyrin-Biroulet and Rubin signal a strategic focus on disease modification and fibrosis, areas with significant unmet medical needs. The company’s prodrug platform aims to overcome tolerability issues that have limited systemic PDE4 inhibitors, potentially creating a competitive advantage in the inflammatory and fibrotic disease market.
What we're watching
- Clinical Strategy
- How the new advisors will shape PALI-2108’s Phase 2 trial design and endpoints.
- Regulatory Pathway
- Whether the targeted delivery mechanism will facilitate smoother regulatory approval.
- Competitive Positioning
- The pace at which Palisade can differentiate itself in the crowded IBD therapeutics space.
Related topics